Catalent and Stirling Ultracold today announced a partnership whereby Stirling Ultracold becomes the preferred provider of ULT storage across Catalent’s multiple business units.

Catalent today announced that it has made an investment to expand capabilities at its clinical supply services facility in Philadelphia to support sponsors developing cell and gene therapies.

Catalent announced that its clinical supply experts will be participating in upcoming Global Clinical Supplies Group (GCSG) events, discussing cell and gene therapy supply chains, direct-to-patient (DTP) services, and just-in-time delivery models.

Catalent today announced that two of its clinical supply experts will be participating in upcoming digital events, Clinical Trial Supply Europe and Clinical Trial Supply Roundtable Forum 2021.

Catalent today announced the appointment of Nakaya “Nick” Matsumaru as General Manager of its new clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Passage Bio, Inc. and Catalent today announced that manufacturing operations have commenced to support adeno-associated virus (AAV) production for Passage Bio’s lead gene therapy product candidates for the treatment of rare monogenic CNS disorders.

Catalent’s clinical supply site in Bathgate has won Scottish Engineering’s ‘Vice President Award 2020,’ recognising its continuous improvement programme in core values including “patient first, customer dedication, people, innovation, integrity and excellence.”

Catalent today announced that it will lead multiple workshops and exhibit at the upcoming Global Clinical Supplies Group (GCSG) 2020 Global Virtual Conference, which takes place on Sept. 21-25, 2020.

Catalent today announced that Paul Ingram, Ph.D., Global Director, Strategic Development and Innovation, will present at the upcoming conference, ‘Clinical Trial Supply Forum’.